Zacks.com on MSN3d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...
GlobalData on MSN4d
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
The European Commission (EC) has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI ...
pharmaphorum5d
Pfizer bags EU okay for haemophilia drug Hympavzi
Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the ...
Business Wire5d
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis ...
The Pharma Letter4d
EC approval for Pfizer’s Hympavzi
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...
Pharmabiz4d
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors: New York Thursday, November 21, 2024, 0 ...
Pfizer's HYMPAVZI Approved In EU For Treatment Of Severe Hemophilia A Or B Without Inhibitors
Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI ...
Armed robbery in Revesby4d
EU Greenlights Pfizer's HYMPAVZI for Severe Hemophilia
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the ...
Yahoo Finance2d
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
EU Approval for Pfizer’s Hemophilia Gene Therapy Hympavzi The European Commission granted marketing authorization to Pfizer’s anti-TFPI inhibitor Hympavzi (marstacimab) for the treatment of ...
Pfizer Gets European Approval of Hympavzi Hemophilia Drug
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...
Nasdaq5d
Pfizer's HYMPAVZI Approved In EU For Treatment Of Severe Hemophilia A Or B Without Inhibitors
(RTTNews) - Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI (marstacimab) to treat adults and adolescents with ...
Yahoo Finance4d
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
The European Commission (EC) has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI (marstacimab), to treat prophylaxis of bleeding incidents ...